BNF 84 (British National Formulary) September 2022-March 2023: 84: September 2022 - March 2023
About this deal
Completely free for members, our e-Library contains over 100 essential pharmacy e-Book texts curated by our professionallibrarian, as well as: Physicochemical Principles of Pharmacy in Manufacture, Formulation and Clinical Use - 6th ed. (2016) BNF 78 New drug monographs: Ertugliflozin (Steglatro), Insulin glargine with lixisenatide (Suliqua), Stiripentol (Diacomit)
Practical and evidence based, British National Formulary (BNF) is the only drug formulary in the world that is both independent, and has rigorous, accredited content creation processes.June 2022 Correction of side-effect content in BNF monographs for cetuximab, lenvatinib and regorafenib
The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.BNF 84 New drug monographs: Icosapent ethyl (▼Vazkepa), Baloxavir marboxil (▼Xofluza), Herpes-zoster vaccine [recombinant, adjuvanted] (▼Shingrix) A British National Formulary (BNF) is a medical and pharmaceutical publication that contains information and advice on prescribing and pharmacology, along with specific facts and details about all medicines available on the NHS. The results of this research have enabled us to critically review the information that should be included within specialist drug monographs. “Specialist drug” monographs will contain less detail than a regular monograph within BNF Publications, in a consistent format. A “specialist” monograph will continue to include information to support patient safety and non-specialist patient care (such as important safety information, interactions, side-effects, and contra-indications), but it will not contain information which is within the remit of specialist care (such as doses, and directions for administration). The current level of additional prescribing information has been retained for drug monographs that have a mix of specialist and non-specialist uses (such as methotrexate that is used for both malignancy and rheumatological conditions).